Investigating how changes in the SARS-CoV-2 spike protein affect its behavior and vaccine response
Effect of natural and engineered variations on structure and biophysics of SARS-CoV-2 spike
This study is looking at the spike protein of the SARS-CoV-2 virus to see how changes in it affect how the virus infects cells and how well vaccines work, with the goal of helping to create better vaccines for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11009009 on NIH RePORTER |
What this research studies
This research focuses on understanding the structure and biophysics of the spike protein of the SARS-CoV-2 virus, which is crucial for its ability to infect cells and evade the immune response. By examining both natural and engineered variations of this protein, the research aims to uncover how mutations influence the virus's interaction with antibodies and its overall infectivity. The approach combines advanced simulations, biochemical analysis, and biophysical studies to provide insights that could inform the design of more effective vaccines against emerging variants. Patients may benefit from this research as it seeks to enhance our understanding of the virus and improve vaccine efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of COVID-19 infection, particularly those in areas with high transmission rates or those who may be affected by vaccine-resistant variants.
Not a fit: Patients who are not at risk of COVID-19 or who have already been vaccinated and are not concerned about variants may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that can better combat emerging variants of SARS-CoV-2.
How similar studies have performed: Other research has shown success in understanding viral mutations and their impact on vaccine efficacy, making this approach both relevant and promising.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Acharya, Priyamvada — Duke University
- Study coordinator: Acharya, Priyamvada
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.